Media coverage about Quidel Corporation (NASDAQ:QDEL) has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quidel Corporation earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.2337765828433 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities research analysts recently commented on QDEL shares. Zacks Investment Research cut Quidel Corporation from a “hold” rating to a “strong sell” rating in a research note on Saturday, July 29th. BidaskClub cut Quidel Corporation from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 16th. William Blair raised Quidel Corporation from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 18th. TheStreet cut Quidel Corporation from a “b-” rating to a “c” rating in a research note on Wednesday, July 26th. Finally, Barclays PLC raised their target price on Quidel Corporation from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $31.40.

Shares of Quidel Corporation (QDEL) traded up 0.43% during midday trading on Friday, reaching $32.61. The company’s stock had a trading volume of 132,775 shares. The stock has a 50-day moving average price of $32.13 and a 200-day moving average price of $25.45. The stock’s market cap is $1.09 billion. Quidel Corporation has a 52-week low of $18.25 and a 52-week high of $38.92.

Quidel Corporation (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, July 26th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.18. The firm had revenue of $38.30 million for the quarter, compared to the consensus estimate of $41.91 million. Quidel Corporation had a negative net margin of 0.03% and a negative return on equity of 0.03%. Quidel Corporation’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.11) earnings per share. Equities research analysts anticipate that Quidel Corporation will post $0.28 earnings per share for the current fiscal year.

In other news, SVP Michael Donald Jr. Abney sold 1,173 shares of the stock in a transaction on Friday, July 28th. The stock was sold at an average price of $33.83, for a total transaction of $39,682.59. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Douglas C. Bryant sold 36,000 shares of the stock in a transaction on Monday, July 31st. The shares were sold at an average price of $33.83, for a total value of $1,217,880.00. Following the transaction, the chief executive officer now directly owns 296,493 shares in the company, valued at $10,030,358.19. The disclosure for this sale can be found here. Insiders have sold a total of 227,388 shares of company stock worth $6,951,432 over the last three months. Insiders own 22.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at

Quidel Corporation Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel Corporation (NASDAQ:QDEL)

Receive News & Ratings for Quidel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel Corporation and related companies with's FREE daily email newsletter.